首页 | 本学科首页   官方微博 | 高级检索  
     

丹红注射液对慢性肺源性心脏病患者肝细胞生长因子与肺动脉高压的影响
引用本文:卢明珍. 丹红注射液对慢性肺源性心脏病患者肝细胞生长因子与肺动脉高压的影响[J]. 实用心脑肺血管病杂志, 2012, 20(9): 1543-1545
作者姓名:卢明珍
作者单位:山西省临汾市第二人民医院内科,041000
摘    要:
目的探讨肝细胞生长因子(HGF)与慢性肺源性心脏病的关系,揭示丹红注射液抑制肺动脉高压的作用机制。方法将符合诊断标准的56例肺源性心脏病患者随机分为治疗组和对照组各28例。对照组采用常规治疗,即持续低流量吸氧、抗感染、改善通气、祛痰止咳、平喘、强心利尿、扩血管、纠正水电解质紊乱与酸碱平衡失调等综合治疗。治疗组除按对照组上述方法处理外,加用丹红注射液20 ml加入5%葡萄糖或0.9%氯化钠溶液250 ml中静脉滴注,1次/d,14 d为1个疗程。两组均于治疗前后测定肺动脉压、做血气分析、判定疗效,并采血检测血浆HGF浓度。结果与对照组相比,治疗组经加用丹红注射液治疗后,患者的临床症状好转;肺动脉高压、PaCO2降低,PaO2升高(P<0.05,P<0.01),同时血浆HGF降低。结论加用丹红治疗可以明显改善慢性肺心病患者的临床症状和血气分析指标,降低肺动脉压力,同时伴随血清HGF含量的明显降低,提示丹红治疗可能通过某些途径刺激肺心病患者肺血管内皮HGF表达升高,这可能是其降低肺动脉压,发挥抗肺心病的重要作用机制之一。

关 键 词:丹红注射液  肺心病  胞间信号肽类和蛋白质  高血压,肺性

Effects of Danhong Injection on Hepatocyte Growth Factor and Pulmonary Artery Pressure in Patients with Chronic Pulmonary Heart Disease
LU Ming-zhen. Effects of Danhong Injection on Hepatocyte Growth Factor and Pulmonary Artery Pressure in Patients with Chronic Pulmonary Heart Disease[J]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease, 2012, 20(9): 1543-1545
Authors:LU Ming-zhen
Affiliation:LU Ming-zhen.Department of Respiratory Medicine,the Second People′s Hospital of Linfen City,Linfen 041000,China
Abstract:
Objective To reveal the relationship of chronic pulmonary heart disease with the hepatocyte growth factor(HGF),and to explore the action mechanism of Danhong injection for pulmonary hypertension pressure.Methods Fifty-six patients with chronic pulmonary heart disease were randomized into 2 groups:control group(n=28) and treatment group(n=28).The patients in control group were given oxygen,anti-infection,sputum diluent,antiasthmatic drugs,correcting acid-base imbalance and electrolyte disturbance as conventional therapy.The patients in treatment group were treated with the conventional therapy combined with Danhong injection(Danhong 20ml intravenous drip with normal saline 250ml or glucose,once a day,continuous use of 14 days).pulmonary artery pressure and blood gas analysis were measured and plasma samples were collected for determination of hepatocyte growth factor(HGF) before treatment and at the 14th days by treatment in 2 groups.Results Compared with control group,clinical symptoms,the changes of blood gas analysis and pulmonary artery pressure were significantly improved.At same time,plasma HGF increased obviously in treatment group.Conclusion Danhong injection can reduce pulmonary artery pressure and improve the changes of blood gas analysis in patients with chronic pulmonary heart disease,It may be one of the important mechanisms for Danhong injection to protect vascular endothelial function effectively and to increase expression of hepatocyte growth factor.
Keywords:Danhong injection  Pulmonary heart disease  Hepatocyte growth factor  Hyprtension,pulmonary
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号